Use of PillCam ESO2 in Triaging Patients Present With Upper GIB

The Use Of PillCam Esophagus In Triaging Patients Presented With Upper Gastrointestinal Bleeding

Background

• Patients presented to hospital with coffee ground vomiting and black stool may not be actually having upper gastrointestinal bleeding (UGIB)
• Hospital admission can be avoided if serious UGIB can be excluded
• To date, the only useful tool to triage patient for hospital admission in UGIB is by using clinical score such as Rockall score or Blatchford score
• These scores are cumbersome and only exclude the most benign cases, but they are not useful in differentiating those who needs intervention
• In our pilot study, investigators found that capsule endoscopy can be used to identify patients with fresh blood and real coffee ground substance in the stomach and it is superior to nasogastric tube
• Most of UGI lesions leading to bleeding can be diagnosed by capsule endoscopy

Objectives The current study is designed

1. to validate capsule endoscopy is an effective method in identifying patients with UGIB
2. to study whether the capsule endoscopy can reduce requirement of hospital admission in patients with suspected UGIB
3. to study if capsule endoscopy can help to identify patients with UGIB that may require urgent (within 24 hours) endoscopy and intervention
4. to study the cost-effectiveness of capsule endoscopy being used as a triaging tool in the management of UGIB
5. to compare the effectiveness of capsule endoscopy against Blatchford score in identifying patients with UGIB that may require endoscopic intervention.

Study Overview

• Status: Completed
• Conditions: Upper Gastrointestinal Bleeding
• Intervention / Treatment: Device: PillCam ESO2

Detailed Description

Hypothesis PillCam Esophagus is effective in identifying genuine UGIB and hence able to reduce hospital admission due to unsubstantiated UGIB cases

Methodology

• Patients presented to the Accident & Emergency Department (A&ED) of the Prince of Wales Hospital Hong Kong with symptoms suggestive of UGIB will be recruited into this study

• Patients will receive the following tests

  • Complete blood count
  • Coagulation profile
  • Renal and liver function tests
  • Hourly BP, Pulse up to 6 hours
  • Glasgow Blatchford score calculated on admission

• Randomization

  • Capsule Group: Capsule Endoscopy (CE) by using PillCam Esophagus (PillCam ESO) OR
  • Standard group: Hospitalization and Standard of Care
• The video in capsule endoscopy will be read by trained personnel who have undergone at least one hour lecture about realtime reviewing.
• Legally a patient has to be signed off by a clinician within 6 hours. The finding of fresh blood or coffee ground will be documented. Upper GI pathology that may lead to bleeding will also be recorded.

Capsule Endoscopy (CE) After confirming patient has been fasted for at least 5 hours, the subject ingested the PillCam® ESO 2 (Given Imaging Ltd., Yoqneam, Israel) (PillCam ESO) using the Simplified Ingestion Procedure.

Thirty to sixty minutes prior to capsule ingestion, each subject received a single dose of intravenous Maxolon 10mg. Intravenous Maxolon, through its motilin receptor agonist effect, has been shown to promote gastric motility and improve visualization of the gastric mucosa at endoscopy. Moreover, use of Maxolon was thought to facilitate the capsule entering the duodenum.

Using the REAL time viewer, UGI tract images (esophagus to the second portion of the duodenum) were obtained in real time at the patient's bedside. The video images that are transmitted by the PillCam ESO 2 are displayed in real time on the tablet computer screen.

Each subject is also fitted with and wore the standard CE sensor array and data recorder so that a full-length CE video recording can be obtained for subsequent capsule workstation downloading and complete review.

Other demographic data and parameters for Blatchford score calculation will be collected. 10 ml of blood will be taken for routine blood checking. Patients will receive standard care according to EGD findings.

• Study Type: Interventional
• Enrollment (Actual): 68
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Individual aged ≥ 18 years presenting to the emergency department with acute, overt UGIB defined as coffee ground vomiting and/or melena

Exclusion Criteria:

• UGIB with hemodynamic shock (BP<90mmHg and pulse>120 per minutes) requiring urgent endoscopy,
• UGIB with fresh hematemesis requiring urgent endoscopy
• dysphagia, odynophagia, swallowing disorder, Zencker's diverticulum, suspected bowel obstruction or bowel perforation,
• prior bowel obstruction, gastroparesis or known gastric outlet obstruction, Crohn's disease, past GI tract surgery.
• presence of an electromedical device (pacemaker or internal cardiac defibrillator),
• altered mental status (e.g., hepatic encephalopathy) that would limit patient ability in swallowing the capsule, pregnancy and/or lactating, allergy to conscious sedation medications, allergy to Maxolon, unwillingness to swallow the capsule, patient expected to undergo Magnetic Resonance Imaging examination within 7 days of ingesting the capsule, patient on medications that may coat the upper GI tract such as antacids or sucralfate, or inability to provide written informed consent.
• Allergy to Maxolon
• Patients with known Esophageal Varices or Gastric Varices with or without prior bleeding episodes
• Known upper/ lower GI cancer (eg, cancer of esophagus, stomach, small bowel, colon) or hepatocellular carcinoma or pancreatic cancer

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Capsule group: PillCam ESO2; Perform capsule endoscopy and esophagogastroduodenoscopy will be preformed within 24 hours after capsule ingestion	Device: PillCam ESO2; Capsule endoscopy
No Intervention: Standard group; Perform standard esophagogastroduodenoscopy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The number of patients requiring hospital admission	Patients with evidence of significant bleeding will be admitted to ward and receive early endoscopy (EGD)	24 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical rebleeding	Recurrent GI bleeding	30 days
Mortality	Death rate	30 days
Cost of management in different strategies	Cost of management in different strategies	One year
Comparing the effectiveness of CE against Glasgow Blatchford score in identifying patients with UGIB that may require endoscopic intervention	Using Glasgow Blatchford score	30 days

Collaborators and Investigators

• Sponsor: Chinese University of Hong Kong
• Investigators: Study Director: Jessica Y.L. Ching, MPH, Chinese University of Hong Kong

Publications and helpful links

General Publications

• Sung JJ, Tang RS, Ching JY, Rainer TH, Lau JY. Use of capsule endoscopy in the emergency department as a triage of patients with GI bleeding. Gastrointest Endosc. 2016 Dec;84(6):907-913. doi: 10.1016/j.gie.2016.04.043. Epub 2016 May 6.

Study record dates

Study Major Dates

• Study Start: November 1, 2013
• Primary Completion (Actual): April 1, 2015
• Study Completion (Actual): April 1, 2016

Study Registration Dates

• First Submitted: May 12, 2015
• First Submitted That Met QC Criteria: May 13, 2015
• First Posted (Estimate): May 18, 2015

Study Record Updates

• Last Update Posted (Actual): April 25, 2017
• Last Update Submitted That Met QC Criteria: April 23, 2017
• Last Verified: April 1, 2017

More Information

Terms related to this study

• Keywords: emergency department; Gastrointestinal bleeding; PillCam ESO2
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Gastrointestinal Diseases; Hemorrhage; Gastrointestinal Hemorrhage
• Other Study ID Numbers: ESO2

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No